BNP/CALL/ELI LILLY & CO/720/0.1/20.12.24

BNP/CALL/ELI LILLY & CO/720/0.1/20.12.24 Stock

DE000PC251H4

Market Closed - Boerse Frankfurt Warrants 15:50:27 2024-07-11 EDT
22.35 ^EUR	-2.44%

Current month	+6.36%
1 month	+25.93%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart BNP/CALL/ELI LILLY & CO/720/0.1/20.12.24

Latest news about ELI LILLY AND COMPANY

Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	07-11	DJ
Pfizer moves forward with once-daily weight loss drug	07-11	RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating	07-11	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating	07-11	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-11	21.9	-4.41%
24-07-10	22.91	+2.46%
24-07-09	22.36	+6.43%
24-07-08	21.01	+1.11%
24-07-05	20.78	+4.84%

Real-time Boerse Frankfurt Warrants

Last update July 11, 2024 at 03:50 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ELI LILLY AND COMPANY
Issuer	BNP Paribas
WKN	PC251H
ISIN	DE000PC251H4
Date issued	2024-01-10
Strike	720 $
Maturity	2024-12-20 (162 Days)
Parity	10 : 1
Emission price	4.25 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	23.35 €
Lowest since issue	4.08 €
Spread	0.02 €
Spread %	0.09%

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company